Medical Pharmacology Question Bank
Chapter: Chapter 14 — General Anesthesia Pharmacology — Module: Module 2 — Pharmacology of Individual Inhalational Agents
Tier: Tier 1 — Foundational Recall (16 questions)
1. An oral surgeon plans to infiltrate 4 mL of lidocaine with epinephrine 1:100,000 into the surgical site of a patient anesthetized with halothane. Approximately how much epinephrine does this volume deliver, and does this dose exceed the threshold at which halothane sensitization of the myocardium to catecholamine-induced ventricular arrhythmias becomes clinically significant?
ANSWER: C
Rationale:
Epinephrine 1:100,000 contains 10 mcg of epinephrine per milliliter, so 4 mL delivers approximately 40 mcg. In a 70 kg adult, this corresponds to approximately 0.57 mcg/kg — below the 1.5 to 2 mcg/kg threshold at which halothane sensitization of the myocardium to catecholamine-induced ventricular arrhythmias becomes significant. However, in a lighter patient or with larger volumes, the threshold is easily reached. More importantly, the 1.5 to 2 mcg/kg threshold for halothane is dramatically lower than the threshold for isoflurane (approximately 6 mcg/kg) and for sevoflurane and desflurane (even higher). Halothane's unique ability to sensitize the myocardium to catecholamines — through mechanisms involving altered calcium handling and membrane effects on ventricular myocytes — makes epinephrine co-administration during halothane anesthesia a specific clinical concern requiring strict dose limitation, in contrast to modern volatile agents where the threshold is substantially higher and the risk correspondingly lower. Option A: This option inverts the relative thresholds of halothane and isoflurane. Halothane has the lower arrhythmia threshold (approximately 1.5 to 2 mcg/kg) and isoflurane has the higher threshold (approximately 6 mcg/kg) — not the reverse. Halothane is more, not less, sensitive than modern agents, making this option incorrect. Option B: Halothane does sensitize the myocardium to catecholamine-induced arrhythmias, and this sensitization is one of its most important and well-documented clinical properties. Stating that no dose restriction is required during halothane anesthesia contradicts established pharmacology and clinical practice, making this option incorrect. Option C: Correct. Epinephrine 1:100,000 delivers 10 mcg/mL, so 4 mL delivers approximately 40 mcg; halothane's catecholamine sensitization threshold of approximately 1.5 to 2 mcg/kg is far lower than isoflurane's, making dose limitation essential during halothane anesthesia. Option D: Epinephrine 1:100,000 contains 10 mcg/mL, not 1 mcg/mL — 4 mL delivers approximately 40 mcg, not 4 mcg. Additionally, lidocaine does not amplify halothane sensitization through sodium channel blockade; the two mechanisms are pharmacologically independent. The arithmetic error in this option makes it incorrect on its face. Option E: Epinephrine 1:100,000 contains 10 mcg/mL; 4 mL delivers 40 mcg, not 400 mcg. This option overstates the dose by a factor of 10 through a decimal error, and the conclusion that epinephrine is contraindicated with all volatile agents is not supported — modern agents have substantially higher arrhythmia thresholds, making routine epinephrine use in local anesthetics clinically acceptable with them. This option is incorrect.
2. An anesthesiologist setting up the operating room for a case planned to use desflurane for maintenance discovers that only a standard variable-bypass vaporizer is available — the type used for isoflurane and sevoflurane. Why cannot this vaporizer be used to deliver desflurane, and what does desflurane require instead?
ANSWER: A
Rationale:
Desflurane's near-room-temperature boiling point of approximately 22.8°C is the defining physical property that necessitates its specialized delivery system. Because it boils near ambient temperature, a standard variable-bypass vaporizer — which relies on the agent remaining liquid at room temperature and vaporizing predictably into a carrier gas stream — cannot control desflurane delivery. Small changes in ambient temperature near the boiling point would cause uncontrolled and unpredictable vaporization, delivering dangerously variable inspired concentrations. Desflurane therefore requires a heated, pressurized vaporizer (the Tec 6 and its equivalents) that maintains the agent as a liquid under elevated pressure at a controlled temperature above its boiling point and meters precise concentrations electronically. This vaporizer requirement adds cost and equipment complexity but is non-negotiable for safe desflurane delivery. All other volatile agents in common use — isoflurane, sevoflurane, halothane, enflurane — have boiling points well above room temperature and are compatible with standard variable-bypass vaporizers. Option A: Correct. Desflurane's boiling point of approximately 22.8°C is near room temperature, making standard variable-bypass vaporizers unsafe; a heated, pressurized vaporizer is required to maintain controlled, predictable delivery. Option B: The blood:gas partition coefficient determines blood solubility and induction speed, not vaporizer behavior. There is no mechanism by which low blood solubility causes condensation in vaporizer tubing; desflurane's vaporizer requirement is entirely explained by its near-room-temperature boiling point, not its partition coefficient, making this option incorrect. Option C: The oil:gas partition coefficient reflects lipid solubility and anesthetic potency, not the physical behavior of the agent in a vaporizer. Variable-bypass vaporizers are not calibrated based on oil:gas coefficients; they operate based on vapor pressure and temperature, making this option incorrect. Option D: Desflurane does not chemically react with metal vaporizer components to produce toxic degradation products. It is one of the most metabolically and chemically stable volatile agents, undergoing less than 0.02% hepatic metabolism. Chemical reactivity is not the reason for its specialized vaporizer requirement, making this option incorrect. Option E: Standard variable-bypass vaporizers are not mechanically limited to 5% maximum output; isoflurane vaporizers, for example, can deliver up to 5% and sevoflurane vaporizers up to 8%. The reason desflurane requires a specialized vaporizer is its near-room-temperature boiling point, not a MAC-related concentration ceiling in standard equipment, making this option incorrect.
3. A patient under isoflurane anesthesia develops a fall in mean arterial pressure accompanied by an increase in heart rate. A student asks why the heart rate is rising rather than falling, given that the blood pressure is low. Which of the following correctly explains this hemodynamic pattern and distinguishes it from the pattern seen with halothane at equivalent anesthetic depth?
ANSWER: D
Rationale:
The divergent heart rate responses to isoflurane and halothane at equivalent anesthetic depths reflect fundamentally different primary hemodynamic mechanisms. Isoflurane is a potent peripheral vasodilator — it reduces systemic vascular resistance predominantly through relaxation of vascular smooth muscle. The resulting fall in blood pressure is detected by arterial baroreceptors, which trigger a compensatory increase in sympathetic outflow, producing reflex tachycardia and partially maintaining cardiac output despite reduced afterload. Myocardial contractility is only minimally depressed at clinical doses. Halothane, by contrast, produces relatively modest peripheral vasodilation; its hypotension arises primarily from direct myocardial depression through impaired intracellular calcium handling, reducing heart rate, contractility, and cardiac output. Without the vasodilation-driven baroreceptor stimulus, there is no trigger for reflex tachycardia, and the direct depressant effect on the sinoatrial node produces the characteristic bradycardia. This mechanistic distinction — vasodilation with reflex tachycardia versus myocardial depression with bradycardia — is one of the most clinically important pharmacological differences between the two agents. Option A: Isoflurane does not directly stimulate cardiac beta-1 adrenergic receptors, and halothane does not exhibit muscarinic M2 agonism. The tachycardia of isoflurane is an indirect baroreceptor-mediated reflex response to vasodilation, not direct adrenergic receptor activation, making this option mechanistically incorrect. Option B: Isoflurane does not block muscarinic M2 receptors. Anticholinergic-type tachycardia from M2 blockade is the mechanism of atropine and glycopyrrolate, not volatile anesthetics. The tachycardia with isoflurane is a sympathetically mediated baroreceptor reflex, making this option incorrect. Option C: Halothane does not produce peripheral vasodilation as its primary hemodynamic mechanism — its primary mechanism is direct myocardial depression. The statement that both agents produce peripheral vasodilation as their primary mechanism is factually incorrect for halothane, making this option incorrect. Option D: Correct. Isoflurane's peripheral vasodilation triggers a baroreceptor-mediated reflex tachycardia that maintains cardiac output; halothane's primary direct myocardial depression without significant vasodilation produces bradycardia without a compensatory reflex increase in heart rate. Option E: Isoflurane does not inhibit norepinephrine re-uptake at cardiac sympathetic terminals. Norepinephrine re-uptake inhibition is the mechanism of tricyclic antidepressants and cocaine, not volatile anesthetics. Attributing isoflurane's tachycardia to this mechanism is pharmacologically unfounded, making this option incorrect.
4. Following a 4-hour sevoflurane anesthetic, a patient's postoperative serum inorganic fluoride level is measured at 58 µmol/L. The anesthesiology resident is concerned because this exceeds the 50 µmol/L threshold historically associated with nephrotoxicity from methoxyflurane. How should this finding be interpreted?
ANSWER: B
Rationale:
Sevoflurane undergoes approximately 3 to 5% hepatic metabolism via CYP2E1, generating inorganic fluoride ions and hexafluoroisopropanol (HFIP). Serum fluoride levels after sevoflurane can transiently exceed 50 µmol/L — the threshold that was historically associated with nephrotoxicity in patients receiving methoxyflurane, a now-abandoned volatile agent that caused high-output renal failure through fluoride-mediated tubular toxicity. However, the nephrotoxicity threshold derived from methoxyflurane does not translate directly to sevoflurane for two important reasons: first, methoxyflurane caused nephrotoxicity through extensive intrarenal metabolism that generated fluoride directly within the renal tubular cells; sevoflurane's intrarenal metabolism is limited, meaning the kidney is not exposed to the same local fluoride concentrations despite similar systemic levels. Second, HFIP, sevoflurane's co-metabolite, does not appear directly nephrotoxic at clinically generated concentrations. Multiple prospective clinical studies have failed to demonstrate clinically significant renal dysfunction attributable to sevoflurane at standard doses and flow rates, and the finding of a serum fluoride level mildly above 50 µmol/L should not trigger nephrotoxicity management in an otherwise well patient. Option A: A transiently elevated serum fluoride level after sevoflurane does not confirm ongoing nephrotoxicity or warrant dialysis preparation. Clinical studies have not demonstrated sevoflurane-related renal failure at these concentrations, and routine monitoring of renal function is appropriate but escalation to dialysis planning based solely on this fluoride level is not warranted, making this option incorrect. Option B: Correct. Sevoflurane CYP2E1 metabolism can generate serum fluoride above 50 µmol/L, but clinical nephrotoxicity has not been demonstrated because of limited intrarenal metabolism and the non-nephrotoxic nature of HFIP; the methoxyflurane-derived threshold does not apply directly to sevoflurane. Option C: While CYP2E1 polymorphisms can affect metabolism rates, a serum fluoride of 58 µmol/L after a 4-hour sevoflurane anesthetic is within the expected range for normal metabolizers and does not indicate an ultrarapid metabolizer genotype. Avoiding all halogenated agents on this basis is not supported by evidence, making this option incorrect. Option D: Compound A is a distinct degradation product formed from sevoflurane-CO₂ absorbent interaction; it is not the cause of elevated serum fluoride levels, which arise from hepatic CYP2E1 metabolism. The serum fluoride level does not confirm low fresh gas flows or compound A accumulation — the two pathways are independent, making this option incorrect. Option E: Sevoflurane is metabolized by CYP2E1 and does generate inorganic fluoride — this is well established. A serum fluoride level of 58 µmol/L after sevoflurane anesthesia is an expected and pharmacologically explicable finding, not a measurement error, making this option incorrect.
5. An anesthesiologist induces anesthesia with 70% nitrous oxide (N₂O) combined with 1% sevoflurane. The patient loses consciousness more rapidly than would be expected from 1% sevoflurane alone. Which pharmacological phenomenon accounts for this accelerated induction, and what is its mechanism?
ANSWER: E
Rationale:
The second gas effect is a kinetic phenomenon arising from the large-volume uptake of nitrous oxide from the alveolus into the pulmonary capillary blood. Because nitrous oxide is administered at high concentrations (50 to 70% of inspired gas) and has a relatively high uptake rate early in administration, its absorption from the alveolus is substantial enough to reduce total alveolar gas volume. This reduction in volume concentrates the remaining alveolar components — including any co-administered volatile agent such as sevoflurane — raising their alveolar partial pressures above what their inspired concentrations alone would predict. The higher alveolar partial pressure drives faster diffusion into pulmonary capillary blood and, ultimately, faster equilibration in the brain. The second gas effect is most clinically relevant at the onset of nitrous oxide administration when uptake rates are highest. It is the kinetic complement to the concentration effect (the concentration of nitrous oxide in the inspired mixture also augments its own alveolar partial pressure rise) and both phenomena apply simultaneously when nitrous oxide is used at high concentrations during induction. Option A: The concentration effect is a related but distinct phenomenon from the second gas effect. The concentration effect describes how the large-volume uptake of nitrous oxide augments its own alveolar partial pressure rise; the second gas effect describes how this uptake concentrates co-administered agents. The option describes the concentration effect rather than the mechanism of accelerated co-agent induction, making it an incomplete and mislabeled answer for this specific question, making it incorrect. Option B: While nitrous oxide does inhibit NMDA receptors and does reduce sevoflurane MAC when used concurrently — the MAC-sparing effect — this is a pharmacodynamic interaction, not the kinetic phenomenon asked about in the question. The MAC-sparing effect explains why less sevoflurane is needed for anesthesia, not why equilibration is faster, making this option incorrect. Option C: Nitrous oxide's mild sympathomimetic effect does slightly increase cardiac output, but this is not the mechanism of accelerated co-agent induction. The relevant mechanism is alveolar gas concentration through large-volume N₂O uptake, not hemodynamic augmentation of cerebral drug delivery, making this option incorrect. Option D: Nitrous oxide is not preferentially absorbed by alveolar macrophages; it diffuses freely across the alveolar-capillary membrane into pulmonary capillary blood. Macrophage uptake is pharmacologically negligible and not a recognized mechanism of inhalational anesthetic kinetics, making this option incorrect. Option E: Correct. The second gas effect describes concentration of co-administered volatile agents in the alveolus following large-volume N₂O uptake, accelerating their alveolar partial pressure rise and hastening induction.
6. A patient is receiving enflurane anesthesia at 1.5 MAC with normocapnia for an elective procedure. A medical student asks whether this patient is at risk for intraoperative seizures given enflurane's known epileptogenic potential. Which of the following most accurately characterizes the conditions under which enflurane produces clinically significant epileptogenic EEG (electroencephalogram) activity?
ANSWER: C
Rationale:
Enflurane's epileptogenic potential is dose-dependent and is substantially modified by arterial CO₂ levels. The characteristic EEG pattern — high-amplitude spike-and-wave complexes — appears primarily at concentrations above approximately 2 MAC, and at standard clinical doses of 1.0 to 1.5 MAC with normocapnia, clinically significant seizure activity is uncommon. However, hypocapnia (low PaCO₂) is a well-established independent potentiator of enflurane's epileptogenic effect: low CO₂ increases neuronal excitability through cerebrovascular constriction and changes in ionized calcium, lowering the seizure threshold and making epileptiform activity more likely at any given enflurane concentration. The combination of high concentration (above 2 MAC) and hypocapnia represents the highest-risk scenario. In the scenario described — 1.5 MAC with normocapnia — the patient is at substantially lower risk than at high concentrations with hypocapnia, though the theoretical risk is not zero. Enflurane remains formally contraindicated in patients with known seizure disorders regardless of concentration or ventilation strategy. Option A: Enflurane does not produce epileptogenic EEG activity at all concentrations above 0.5 MAC; the risk is primarily concentration-dependent with a threshold around 2 MAC, and low-to-moderate concentrations with normocapnia carry substantially lower risk. Enflurane has also not been withdrawn from all countries — it remains available in some settings — making this option incorrect. Option B: Hypocapnia amplifies but does not solely determine enflurane's epileptogenic potential. High concentration is the primary driver; normocapnia reduces but does not eliminate the risk at concentrations above 2 MAC. The claim that seizures cannot occur above 2 MAC if normocapnia is maintained overstates the protective effect of CO₂ management, making this option incorrect. Option C: Correct. Enflurane's epileptogenic activity is primarily concentration-dependent (threshold approximately 2 MAC) and is amplified by hypocapnia; at 1.5 MAC with normocapnia the risk is substantially lower, though the agent is still contraindicated in patients with seizure disorders. Option D: Enflurane's epileptogenic potential is strongly concentration-dependent, increasing markedly above 2 MAC; it does not appear at induction concentrations of 0.5 MAC in the same way or to the same degree. Stating that the effect is identical at all concentrations is inconsistent with its established dose-dependent pharmacology, making this option incorrect. Option E: Enflurane can produce EEG spike-and-wave activity and intraoperative seizures in neurologically normal patients at high concentrations with hypocapnia — it is not exclusively a risk in patients with pre-existing epilepsy. The contraindication in epilepsy reflects heightened susceptibility, not that the risk is absent in normal patients at extreme conditions, making this option incorrect.
7. Halothane hepatotoxicity is classified into two distinct syndromes. Which of the following correctly distinguishes Type I from Type II halothane hepatotoxicity in terms of incidence, mechanism, severity, and the role of re-exposure?
ANSWER: A
Rationale:
Halothane hepatotoxicity is classified into two pharmacologically and clinically distinct syndromes. Type I is a mild, self-limited hepatotoxicity characterized by transient asymptomatic or minimally symptomatic elevation of hepatic transaminases, occurring in approximately 20 to 30% of patients after halothane exposure. It results from direct hepatocellular injury by reactive metabolites — primarily trifluoroacetyl chloride produced by oxidative CYP2E1 metabolism — and is not immune-mediated. It resolves spontaneously without specific treatment. Type II halothane hepatotoxicity is a rare but severe and potentially fatal immune-mediated fulminant hepatitis, occurring in approximately 1 in 10,000 to 1 in 30,000 exposures. The mechanism involves covalent binding of trifluoroacetyl chloride to hepatic microsomal proteins, generating trifluoroacetylated protein adducts that the immune system recognizes as foreign neoantigens. This immune sensitization on first exposure sets the stage for a much more aggressive and accelerated immune-mediated hepatic injury on re-exposure, making prior halothane exposure a critical risk factor. Mortality when Type II hepatitis occurs is approximately 50%. The risk increases substantially with repeated exposures at short intervals, which is why re-exposure within 6 months is particularly dangerous. Option A: Correct. Type I is a direct-toxic, common, self-limited transaminase elevation; Type II is a rare immune-mediated fulminant hepatitis with high mortality, requiring trifluoroacetylated neoantigen sensitization and dramatically worsened by re-exposure. Option B: This option inverts the characterization: Type II is the rare, severe form, not a common mild form; Type I is the mild common form, not the rare fulminant form. Additionally, bromide ion — a reductive metabolite — is not the primary driver of either hepatotoxicity syndrome; trifluoroacetyl chloride from oxidative metabolism is the key reactive intermediate, making this option incorrect. Option C: Both types of halothane hepatotoxicity are not immune-mediated. Type I is a direct toxic injury, not IgE-mediated hypersensitivity. Type II is immune-mediated but involves cell-mediated and IgG mechanisms related to neoantigen recognition, not immediate IgE-mediated hypersensitivity. The immunoglobulin classification described is not accurate, making this option incorrect. Option D: This option inverts the metabolic mechanisms. Oxidative CYP2E1 metabolism generates trifluoroacetyl chloride and is the primary mechanism of both types; reductive metabolism generates bromide ion but is not the primary driver of the hepatotoxicity classification. Additionally, Type I does not require re-exposure — it occurs on first exposure — while Type II is dramatically worsened by re-exposure, making this option incorrect. Option E: Type I halothane hepatotoxicity is not restricted to patients with pre-existing liver disease; it occurs broadly after halothane exposure through a direct metabolic mechanism. The characterization of who is affected does not accurately describe the established pharmacological distinction between the two syndromes, making this option incorrect.
8. An anesthesiology department is reviewing its environmental impact as part of a sustainability initiative. The committee asks which inhalational anesthetic agent contributes most to greenhouse gas emissions on a per-molecule basis, and what has been the regulatory response in some countries. Which of the following correctly identifies the agent and describes the response?
ANSWER: D
Rationale:
Desflurane has a global warming potential approximately 3,500 times that of CO₂ over a 100-year horizon, the highest of any currently used anesthetic agent. This dramatically exceeds the global warming potential of isoflurane (approximately 510 times CO₂) and sevoflurane (approximately 130 times CO₂). The environmental impact of desflurane has become a significant concern in anesthesiology sustainability discussions, and it has been withdrawn from clinical use or substantially restricted in the United Kingdom, several Scandinavian countries, and other parts of Europe on environmental grounds. Professional anesthesiology societies in multiple countries have issued guidance recommending reduction or elimination of desflurane use. Paradoxically, desflurane's near-zero hepatic metabolism — the property that eliminates concern about hepatotoxic and nephrotoxic metabolites — also means the molecule is exhaled essentially unchanged and released into the atmosphere unmodified, maximizing its environmental impact. This creates a situation where the pharmacological advantage of metabolic inertness is directly offset by an environmental disadvantage. Option A: Nitrous oxide does have a significant global warming potential and contributes to ozone depletion, but its global warming potential per molecule is considerably lower than desflurane's. Nitrous oxide has not been banned entirely in anesthesia in multiple countries; efforts to reduce its use focus on high-risk PONV patients and environmental scavenging improvements, making this option incorrect. Option B: Compound A is formed in the breathing circuit from sevoflurane-CO₂ absorbent interaction and is a local renal toxin concern (in rats), not a greenhouse gas contributor. The environmental impact of sevoflurane relates to the sevoflurane molecule itself, not compound A; sevoflurane's global warming potential is approximately 130 times CO₂ — considerably lower than desflurane, making this option incorrect. Option C: Isoflurane's global warming potential is approximately 510 times that of CO₂ — significant but substantially lower than desflurane's approximately 3,500. Isoflurane has not been subject to the same level of regulatory restriction as desflurane, and mandatory EU scavenging requirements based on isoflurane's global warming potential alone are not accurately described in this option, making it incorrect. Option D: Correct. Desflurane's global warming potential of approximately 3,500 times CO₂ is the highest of any anesthetic agent, leading to its withdrawal or restriction in the UK and several European countries on environmental grounds. Option E: Halothane does contain bromine, which can contribute to ozone depletion, but this is a distinct concern from global warming potential. Halothane's global warming potential is lower than desflurane's, and the Montreal Protocol concern about brominated compounds applies to halothane but does not make it the agent with the highest global warming potential among currently used agents. The framing of this option conflates ozone depletion with global warming and misidentifies the agent with the highest global warming potential, making it incorrect.
9. Several clinical studies have suggested that sevoflurane may confer cardioprotective benefits beyond its anesthetic effect. Which of the following correctly describes the proposed mechanism and the clinical context in which this property has been investigated?
ANSWER: B
Rationale:
Sevoflurane has been investigated for cardioprotective properties beyond anesthesia in the context of cardiac surgery and procedures involving myocardial ischemia-reperfusion. The proposed mechanism is anesthetic preconditioning — a phenomenon whereby brief exposure to an anesthetic agent triggers endogenous protective intracellular signaling cascades that reduce subsequent ischemia-reperfusion injury. For sevoflurane, activation of mitochondrial ATP-sensitive potassium (KATP) channels has been identified as a key step in this protective pathway; KATP channel opening modulates mitochondrial membrane potential and attenuates the calcium overload and reactive oxygen species generation that drive reperfusion injury. Multiple clinical and laboratory studies have shown reductions in cardiac biomarker release (troponin I) and improvements in left ventricular function in patients undergoing coronary artery bypass grafting with sevoflurane compared to total intravenous anesthesia. However, the overall clinical magnitude of this benefit in routine practice — including effects on hard outcomes such as myocardial infarction and mortality — continues to be investigated and has not been definitively established in all patient populations. Option A: Sevoflurane does not block cardiac beta-1 adrenergic receptors; this is the mechanism of beta-blockers such as metoprolol. The cardioprotective mechanism described for sevoflurane involves KATP channel-mediated preconditioning, not adrenergic blockade, and while sevoflurane has been studied in cardiac surgery, its use is not currently incorporated into guidelines as equivalent to beta-blocker therapy, making this option incorrect. Option B: Correct. Sevoflurane exhibits myocardial preconditioning through mitochondrial KATP channel activation, reducing ischemia-reperfusion injury; the clinical magnitude of benefit remains under investigation. Option C: Sevoflurane does not exert cardioprotection through direct free-radical scavenging by its fluorine substituents. The fluorine atoms confer chemical stability (contributing to low metabolism) but do not function as antioxidants in the mitochondrial matrix. The preconditioning mechanism is receptor-mediated signal transduction, not direct chemical antioxidant activity, making this option incorrect. Option D: While mitochondrial permeability transition pore (mPTP) inhibition is involved in some cardioprotective signaling, describing sevoflurane as causing irreversible mPTP inhibition analogous to cyclosporine overstates both the mechanism and the clinical evidence. Sevoflurane's cardioprotective evidence does not include phase III trial confirmation of the magnitude described, and it has not been established as superior to desflurane on this basis in cardiac surgery guidelines, making this option incorrect. Option E: Sevoflurane does not selectively increase coronary collateral blood flow as a cardioprotective mechanism, and there is no established "reverse steal" pharmacology attributed to it. The coronary steal debate concerns isoflurane, not sevoflurane, and sevoflurane's cardioprotective mechanism is intracellular preconditioning through KATP channels, not vascular redistribution of coronary flow, making this option incorrect.
10. At the end of a 2-hour procedure during which the patient received 65% nitrous oxide (N₂O), the anesthesiologist discontinues the nitrous oxide and switches to 100% oxygen. Without this maneuver, what phenomenon could occur, what is its mechanism, and why does supplemental oxygen prevent it?
ANSWER: E
Rationale:
Diffusional hypoxia — also known as the Fink effect — is the reverse of the second gas effect and occurs at the end of nitrous oxide administration. When nitrous oxide is discontinued, the large quantity dissolved in blood and tissues rapidly diffuses back into the alveolus because the partial pressure gradient now favors movement from blood to alveolar gas. The volume of nitrous oxide entering the alveolus is large enough to dilute both oxygen and CO₂ in the alveolar gas, transiently reducing alveolar PO₂ (and thus arterial PO₂) below inspired levels. In a patient breathing room air at emergence, this dilutional reduction in alveolar oxygen can cause clinically detectable hypoxemia — particularly in elderly patients, those with limited pulmonary reserve, or those whose protective hypoxic ventilatory drive is already blunted. Administering 100% oxygen at the end of the procedure (typically for 5 to 10 minutes) is the standard preventive measure: it ensures that even after the dilutional effect of emerging nitrous oxide, the alveolar oxygen fraction remains high enough to maintain adequate oxygenation. This is a routine practice that effectively eliminates diffusional hypoxia as a clinical risk. Option A: Nitrous oxide withdrawal does not produce a rebound increase in cerebral blood flow that causes central cyanosis through venous oxygen dilution. Diffusional hypoxia is an alveolar gas dilution phenomenon — the mechanism is pulmonary, not cerebrovascular, making this option incorrect. Option B: Abrupt discontinuation of nitrous oxide does not trigger reflex bronchospasm through alveolar gas composition receptors. Bronchospasm is a concern with desflurane (an airway irritant) and in patients with reactive airways disease, but it is not a mechanism of nitrous oxide withdrawal physiology. The relevant phenomenon at nitrous oxide emergence is diffusional hypoxia, making this option incorrect. Option C: Diffusional hypoxia is caused by nitrous oxide (not nitrogen) diffusing from blood into the alveolus at emergence. Nitrogen moves in the opposite direction — out of the alveolus into blood — during induction (the basis of the concentration effect) but is not the gas responsible for diffusional hypoxia at emergence. This option correctly identifies the oxygen-dilution result but misidentifies the responsible gas, making it incorrect. Option D: The described mechanism — reverse diffusion of oxygen from capillaries back into the alveolus — is not how diffusional hypoxia occurs and violates normal gas exchange physiology. The mechanism is nitrous oxide entering the alveolus from blood and diluting alveolar gases, not oxygen moving in reverse from capillaries to alveoli, making this option incorrect. Option E: Correct. Diffusional hypoxia results from rapid nitrous oxide efflux from blood into the alveolus at emergence, diluting alveolar oxygen; 100% oxygen administration prevents clinically significant hypoxemia by maintaining a high alveolar oxygen fraction despite the dilutional effect.
11. A neuroanesthesiologist is selecting a volatile agent for a patient undergoing craniotomy for a large supratentorial tumor with evidence of moderately elevated intracranial pressure (ICP). She wants an agent that can reduce cerebral metabolic rate for oxygen (CMRO₂) and is suitable for procedures requiring careful ICP management. How do isoflurane and halothane compare for this indication, and which is preferred?
ANSWER: C
Rationale:
Isoflurane and halothane both cause dose-dependent cerebral vasodilation, increasing cerebral blood flow (CBF) and potentially raising ICP — a concern in patients with already-elevated intracranial pressure. However, their neurosurgical profiles differ meaningfully. Halothane causes a more pronounced and less controllable increase in CBF and ICP at clinical doses; the CBF increase with halothane is less readily attenuated by hyperventilation, making ICP management more difficult. Isoflurane's CBF increase, while present, is less pronounced than halothane's and is more effectively blunted by moderate hyperventilation, giving the neuroanesthesiologist a greater degree of control. Additionally, isoflurane produces EEG burst suppression at approximately 1.5 to 2 MAC — near-maximal CMRO₂ reduction — which is exploited in procedures requiring temporary arterial occlusion (e.g., temporary clipping during aneurysm surgery) to reduce cerebral metabolic demand during ischemia. Halothane does not provide this degree of metabolic protection as effectively at equivalent depths. For these reasons, isoflurane has a more favorable neurosurgical profile than halothane, and is preferred when a volatile agent is used; sevoflurane and desflurane are also used, but the comparison asked is specifically between isoflurane and halothane. Option A: Halothane does reduce CMRO₂ but does not have the most potent CMRO₂ reduction of any volatile agent. More critically, halothane's reduction in cardiac output does not beneficially offset its ICP-raising cerebral vasodilation; reduced cardiac output lowers cerebral perfusion pressure, which is harmful rather than protective in patients with elevated ICP. This option mischaracterizes both the mechanism and the clinical implication, making it incorrect. Option B: Volatile agents do not all increase CBF and ICP to exactly the same degree at equivalent MAC. Halothane produces a greater and less controllable increase in CBF than isoflurane; these pharmacological differences are clinically meaningful and are precisely why agent selection matters in neurosurgery. The claim that agent selection is based only on cost is incorrect, making this option incorrect. Option C: Correct. Isoflurane is preferred over halothane for neurosurgery with ICP concerns because its cerebral vasodilation is less pronounced, more readily controlled by hyperventilation, and it provides burst suppression for cerebral metabolic protection at high doses. Option D: Isoflurane is not associated with cerebral vasospasm and does not inhibit nitric oxide synthase in a clinically meaningful way. Isoflurane is actually used in neurosurgery in part because of its favorable cerebrovascular profile relative to halothane. This option inverts the correct clinical guidance, making it incorrect. Option E: While total intravenous anesthesia with propofol is an excellent choice for neurosurgery with elevated ICP, it is not the only acceptable technique. Isoflurane (and sevoflurane) at appropriate concentrations with hyperventilation and careful ICP monitoring is a clinically accepted approach used widely in neurosurgical anesthesia. Stating that volatile agents are universally inappropriate for elevated ICP cases overstates the contraindication, making this option incorrect.
12. An obstetrician requests general anesthesia for manual removal of a retained placenta in a patient who has delivered vaginally 45 minutes ago and is bleeding moderately. The anesthesiologist considers using a volatile agent to facilitate uterine relaxation. Which of the following best describes the uterine pharmacology of volatile anesthetics and the specific clinical risk in this scenario?
ANSWER: B
Rationale:
All volatile halogenated anesthetic agents — halothane, isoflurane, sevoflurane, desflurane, and enflurane — produce dose-dependent uterine smooth muscle relaxation at clinical anesthetic concentrations, with the effect becoming clinically significant at concentrations above approximately 0.5 MAC. This property has obstetric utility: when uterine relaxation is needed for procedures such as manual removal of a retained placenta, external version, or intrauterine manipulation, a volatile agent provides pharmacological relaxation of the myometrium that facilitates the procedure. However, the same uterine relaxation that enables the procedure also impairs the uterine contraction that is the primary physiological mechanism of postpartum hemostasis. A uterus that cannot contract adequately after placental removal is at risk for uterine atony — the leading cause of postpartum hemorrhage. Halothane is the most potent uterine relaxant among the volatile agents and was historically the agent of choice for this indication; in high-resource settings, sevoflurane is now more commonly used because of halothane's cardiovascular disadvantages, though both produce adequate relaxation. Nitrous oxide has minimal uterine relaxant effect and does not provide meaningful uterotonic or uterolytic pharmacology at clinical concentrations. Option A: Volatile anesthetic agents do not cause uterine contraction and do not stimulate myometrial oxytocin receptors. Their effect is uterine relaxation, not contraction; the clinical risk is postpartum hemorrhage from impaired uterine tone, not excessive contractility, making this option incorrect. Option B: Correct. All volatile halogenated agents produce dose-dependent uterine relaxation useful for obstetric manipulation, but this same relaxation impairs uterine hemostasis and increases postpartum hemorrhage risk; halothane is the most potent uterine relaxant and was historically used for this indication. Option C: Nitrous oxide has minimal uterine effects at clinically used concentrations and is not a potent uterine relaxant. Its sympathomimetic cardiovascular effect does not provide meaningful protection against uterine atony-related hemorrhage. Nitrous oxide is not the preferred agent for obstetric uterine relaxation, making this option incorrect. Option D: Uterine relaxation from volatile anesthetics is detectable at concentrations as low as 0.5 MAC and becomes clinically significant above this threshold — it is not restricted to concentrations above 2 MAC. The claim that light anesthetic planes are uterine-safe is pharmacologically incorrect and clinically misleading, making this option incorrect. Option E: Volatile anesthetics do not produce uterine relaxation through beta-2 adrenergic receptor agonism. Their mechanism involves direct effects on myometrial smooth muscle calcium signaling and membrane potential, not adrenergic receptor activation. The claim that propranolol can reverse volatile anesthetic-induced uterine relaxation is pharmacologically unfounded, making this option incorrect.
13. A patient with known hypertension and a history of stable angina is receiving desflurane maintenance anesthesia. The anesthesiologist needs to deepen the anesthetic and considers rapidly increasing the inspired desflurane concentration from 4% to 9%. A colleague cautions against doing this rapidly. What is the specific pharmacological mechanism behind this caution, and how should the anesthesiologist proceed?
ANSWER: A
Rationale:
The sympathetic surge associated with rapid increases in desflurane concentration is mediated through stimulation of pulmonary irritant receptors — specialized airway receptors in the trachea, bronchi, and lung parenchyma that respond to chemical irritants and abrupt changes in airway gas composition. Desflurane's pungent, irritating properties, which make it unsuitable for inhalational induction, also activate these receptors when inspired concentration is increased rapidly during maintenance, generating afferent signals that are relayed through vagal afferents to the brainstem and then through sympathetic efferents to the heart and vasculature. The result is a transient but marked increase in sympathetic outflow producing tachycardia and hypertension. In a patient with hypertension and coronary artery disease, this sympathetic surge represents a specific clinical hazard: the resulting increase in heart rate and blood pressure increases myocardial oxygen demand (rate-pressure product) while simultaneously reducing diastolic filling time, potentially precipitating myocardial ischemia or ventricular arrhythmias in vulnerable myocardium. The practical clinical response is to increase desflurane concentration slowly and incrementally — allowing sufficient time between concentration adjustments for the sympathetic response to dissipate — particularly in high-risk cardiac patients. Option A: Correct. Rapid desflurane concentration increases stimulate pulmonary irritant receptors, producing reflex sympathetic activation with tachycardia and hypertension; in a patient with hypertension and coronary artery disease, this risks myocardial ischemia, and gradual concentration increases are required. Option B: Desflurane does not directly activate cardiac beta-1 adrenergic receptors through a structural mechanism specific to its trifluoroethyl ether group. The sympathetic activation is a reflex response mediated through pulmonary irritant receptors, not direct myocardial receptor agonism. While esmolol can be used to attenuate the hemodynamic response, the described mechanism is incorrect, making this option incorrect. Option C: Desflurane does not cause coronary vasospasm through fluorine-mediated nitric oxide synthase inhibition. This mechanism has no pharmacological basis; desflurane's cardiovascular effects at stable maintenance concentrations include modest vasodilation, not coronary vasoconstriction, making this option incorrect. Option D: While desflurane's sympathetic activation results in catecholamine release, the primary mechanism is afferent pulmonary irritant receptor signaling, not direct stimulation of adrenomedullary nicotinic receptors by desflurane itself. Phentolamine pretreatment is not the standard clinical approach; gradual concentration increases are. This option misidentifies the primary mechanism and the preventive strategy, making it incorrect. Option E: Desflurane does not block muscarinic M2 receptors. The tachycardia from desflurane rapid ramp-up is sympathetically mediated through pulmonary irritant receptors, not through removal of vagal tone from M2 blockade. This option incorrectly attributes the mechanism to an anticholinergic effect, making it incorrect.
14. A pediatric anesthesiologist and a geriatric anesthesiologist are discussing postoperative behavioral disturbances in their respective patient populations. The pediatric anesthesiologist describes a 3-year-old thrashing inconsolably in the PACU (post-anesthesia care unit) 10 minutes after a sevoflurane anesthetic, fully resolved within 20 minutes. The geriatric anesthesiologist describes a 78-year-old who was confused and disoriented for 3 days after cardiac surgery. Which of the following best distinguishes these two syndromes?
ANSWER: D
Rationale:
Sevoflurane emergence agitation in children and postoperative delirium in elderly adults are distinct clinical and pathophysiological entities despite their superficial resemblance as post-anesthetic behavioral disturbances. Sevoflurane emergence agitation is a self-limited syndrome occurring specifically in young children — peak incidence in preschool children aged 2 to 5 — and is specifically associated with sevoflurane's rapid offset, which produces a dysphoric transitional state before full cortical reintegration occurs. It begins within minutes of awakening, is characterized by inconsolable crying, thrashing, and failure to recognize caregivers, and resolves spontaneously within 15 to 30 minutes without sequelae. The mechanism is thought to involve the rapid pharmacokinetic offset of sevoflurane's sedative effect, producing a brief period of dysphoric emergence before full consciousness is restored. Postoperative delirium in elderly patients is a fundamentally different syndrome: it is a prolonged disturbance of attention and cognition lasting hours to days (sometimes longer), driven by neuroinflammation, metabolic derangements, sleep-wake cycle disruption, pain, unfamiliar environment, and pre-existing cognitive vulnerability. It is not specific to sevoflurane and occurs with multiple anesthetic techniques. These two syndromes share a post-anesthetic context but differ in age group, duration, pathophysiology, and clinical management. Option A: The two syndromes do not share the same neuroinflammatory pathophysiology; sevoflurane emergence agitation is not a neuroinflammatory process and is not related to neuro-reserve differences between age groups. They are mechanistically distinct, making this option incorrect. Option B: Sevoflurane emergence agitation is specifically associated with sevoflurane rather than all volatile agents equally — sevoflurane's rapid offset is a key contributing factor. Postoperative delirium in elderly patients is not specifically associated with sevoflurane and occurs with multiple anesthetic techniques. This option incorrectly characterizes the agent specificity of each syndrome, making it incorrect. Option C: Sevoflurane emergence agitation is not caused by residual neuromuscular blockade, and postoperative delirium in elderly patients is not caused by opioid-induced hypercapnia. Both proposed mechanisms are pharmacologically unfounded for the syndromes described, making this option incorrect. Option D: Correct. Sevoflurane emergence agitation is a self-limited, sevoflurane-specific dysphoric transitional state peaking in preschool children and resolving within 30 minutes; postoperative delirium in adults is a prolonged neuroinflammatory and metabolic syndrome in elderly patients, pathophysiologically distinct with a different time course and management approach. Option E: The two syndromes are not the same continuum; they differ in mechanism, duration, age distribution, and clinical significance. The claim that the difference is reporting bias is not supported by evidence — the duration difference is real and clinically meaningful, not an artifact of caregiver perception, making this option incorrect.
15. A 58-year-old patient who had vitreoretinal surgery 3 weeks ago with placement of a sulfur hexafluoride (SF₆) intraocular gas bubble for retinal tamponade is scheduled for urgent unrelated abdominal surgery. The ophthalmologist has confirmed the gas bubble is still present. Why is nitrous oxide absolutely contraindicated in this patient, and how long must this contraindication be observed?
ANSWER: E
Rationale:
Intraocular gas bubbles — most commonly SF₆ (sulfur hexafluoride) or C₃F₈ (perfluoropropane) — are placed during vitreoretinal surgery to tamponade retinal tears or detachments. These gases are poorly soluble in blood and diffuse slowly out of the eye; SF₆ typically persists for approximately 2 to 3 months and C₃F₈ for up to 3 months or longer. Nitrous oxide is highly diffusible and, like all gases, equilibrates rapidly across semi-permeable membranes. When administered in the presence of an intraocular gas bubble, nitrous oxide diffuses into the bubble far more rapidly than SF₆ (or C₃F₈) diffuses out — the same physical principle that underlies nitrous oxide's expansion of any air-filled body space. The result is rapid bubble expansion, increasing intraocular pressure to levels that can compress and occlude the central retinal artery, causing ischemic infarction of the retina and permanent, irreversible visual loss. The contraindication to nitrous oxide persists for the entire duration that any intraocular gas is present — it is not a time-limited precaution after surgery but a patient safety absolute until complete gas reabsorption is confirmed. Surgeons typically communicate this restriction to patients and anesthesiologists with written documentation. Option A: Nitrous oxide does not react chemically with SF₆ to produce toxic compounds. The mechanism of harm is purely physical — diffusional expansion of the gas bubble causing intraocular pressure elevation — not a chemical interaction. The claim that this creates a permanent contraindication after SF₆ use is also incorrect; the contraindication resolves when the gas bubble reabsorbs, making this option incorrect. Option B: Nitrous oxide's mild sympathomimetic effect does not significantly raise intraocular pressure through aqueous humor production. The mechanism of harm from nitrous oxide in vitreoretinal gas patients is bubble expansion through diffusion, not systemic pressure effects, making this option incorrect. Option C: Nitrous oxide does not inhibit SF₆ reabsorption by retinal pigment epithelial cells. The contraindication is not about prolonging the gas bubble duration but about the acute danger of bubble expansion causing retinal artery occlusion. The described 2 to 3 day duration of the contraindication is also dramatically underestimated — SF₆ takes weeks to months to reabsorb, making this option incorrect. Option D: The contraindication is not related to nitrous oxide's MAC or to inspired oxygen concentration effects on retinal oxygenation. The mechanism is diffusional expansion of the intraocular gas bubble, not FiO₂ reduction, making this option incorrect. Option E: Correct. Nitrous oxide diffuses into the SF₆ bubble faster than SF₆ exits, causing bubble expansion, acute intraocular pressure elevation, and potential central retinal artery occlusion with permanent visual loss; the contraindication persists until the gas bubble fully reabsorbs.
16. A patient is undergoing right lower lobectomy via thoracotomy. The surgeon requests one-lung ventilation (OLV), during which only the left lung is ventilated while the right lung is deflated in the operative field. The anesthesiologist is using isoflurane for maintenance. Despite appropriate ventilator settings, the patient's SpO₂ (oxygen saturation) falls from 99% to 91% after initiation of OLV. Which pharmacological property of isoflurane contributes to this desaturation, and what physiological mechanism does it impair?
ANSWER: B
Rationale:
Hypoxic pulmonary vasoconstriction (HPV) is a homeostatic reflex in which pulmonary arterioles supplying poorly ventilated or unventilated alveoli constrict in response to low local alveolar PO₂, diverting blood away from non-ventilated regions toward better-ventilated alveoli. This reflex is essential for minimizing intrapulmonary shunt — the fraction of cardiac output that passes through the lung without participating in gas exchange — and for maintaining arterial oxygenation during conditions of regional hypoventilation, including one-lung ventilation. All volatile halogenated anesthetic agents, including isoflurane, inhibit HPV in a dose-dependent manner through mechanisms involving relaxation of pulmonary vascular smooth muscle. During one-lung ventilation, the deflated operative lung would normally trigger robust HPV, markedly reducing its perfusion and limiting shunt fraction. Isoflurane's HPV inhibition attenuates this protective reflex, allowing continued blood flow through the non-ventilated lung and increasing the shunt fraction — the proportion of blood that traverses the atelectatic lung without oxygenation — causing arterial desaturation. This is a pharmacologically relevant contribution to the oxygenation challenge of one-lung ventilation and is one reason total intravenous anesthesia with propofol (which does not inhibit HPV) is sometimes preferred for thoracic procedures requiring prolonged one-lung ventilation in patients with limited pulmonary reserve. Option A: Isoflurane's bronchodilation in the ventilated lung does not cause alveolar overdistension that compresses pulmonary capillaries in a clinically significant way during routine one-lung ventilation. Bronchodilation is generally beneficial, reducing airway resistance; it does not cause shunt through capillary compression, making this option incorrect. Option B: Correct. Isoflurane inhibits HPV in the non-ventilated right lung, allowing continued perfusion of the atelectatic lung and increasing intrapulmonary shunt fraction, which worsens arterial oxygenation during one-lung ventilation. Option C: HPV inhibition affects the non-ventilated lung (the right lung in this scenario), not the ventilated left lung. The reflex is activated by regional alveolar hypoxia in the non-ventilated territories; inhibiting it in the ventilated lung, where alveolar PO₂ is normal, would not produce the described effect. This option misidentifies the lung in which HPV inhibition is clinically relevant, making it incorrect. Option D: Isoflurane produces peripheral systemic vasodilation, not pulmonary vasoconstriction; its cardiovascular effects reduce, not increase, pulmonary artery pressure at clinical doses. The mechanism of shunt worsening during one-lung ventilation is HPV inhibition, not pressure-driven perfusion of the atelectatic lung through elevated pulmonary artery pressure, making this option incorrect. Option E: HPV is activated by regional alveolar hypoxia, not only global hypoxia — the regional collapse of one lung during one-lung ventilation is precisely the stimulus that activates HPV in the non-ventilated lung. This is the well-established physiological basis for the clinical importance of HPV during thoracic surgery. Describing HPV as inactive during regional collapse is factually incorrect, making this option incorrect.